TW202021968A - 用於治療眼部疾病之方法及藥物組合物 - Google Patents

用於治療眼部疾病之方法及藥物組合物 Download PDF

Info

Publication number
TW202021968A
TW202021968A TW108129703A TW108129703A TW202021968A TW 202021968 A TW202021968 A TW 202021968A TW 108129703 A TW108129703 A TW 108129703A TW 108129703 A TW108129703 A TW 108129703A TW 202021968 A TW202021968 A TW 202021968A
Authority
TW
Taiwan
Prior art keywords
individual
camkk2
compound
cells
disease
Prior art date
Application number
TW108129703A
Other languages
English (en)
Chinese (zh)
Inventor
史考特 Ｗ 卡森斯
派瑞亞森 Ｓ 曼杜
大衛 Ｍ 古登
Original Assignee
公爵大學
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 公爵大學 filed Critical 公爵大學
Publication of TW202021968A publication Critical patent/TW202021968A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW108129703A 2018-08-20 2019-08-20 用於治療眼部疾病之方法及藥物組合物 TW202021968A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862719938P 2018-08-20 2018-08-20
US62/719,938 2018-08-20

Publications (1)

Publication Number Publication Date
TW202021968A true TW202021968A (zh) 2020-06-16

Family

ID=69591159

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108129703A TW202021968A (zh) 2018-08-20 2019-08-20 用於治療眼部疾病之方法及藥物組合物

Country Status (14)

Country Link
US (2) US12221447B2 (https=)
EP (1) EP3840745A4 (https=)
JP (1) JP2021534202A (https=)
KR (1) KR20210049857A (https=)
CN (1) CN112654353A (https=)
AU (1) AU2019326448A1 (https=)
BR (1) BR112021003189A2 (https=)
CA (1) CA3109809A1 (https=)
CO (1) CO2021003607A2 (https=)
IL (1) IL280952A (https=)
MX (1) MX2021002028A (https=)
SG (1) SG11202101522WA (https=)
TW (1) TW202021968A (https=)
WO (1) WO2020041344A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019326448A1 (en) 2018-08-20 2021-03-11 Duke University Methods and compositions for drugs to treat ophthalmic diseases
WO2024257328A1 (ja) * 2023-06-16 2024-12-19 千寿製薬株式会社 眼疾患モデル動物
JP7776899B1 (ja) * 2024-06-14 2025-11-27 株式会社坪田ラボ 局所投与用の重症眼表面疾患の処置剤

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4153693B2 (ja) 2001-04-25 2008-09-24 大日本住友製薬株式会社 新規なＣａＭＫＫ阻害剤
GB0600763D0 (en) 2006-01-13 2006-02-22 Crysoptix Ltd 6, 7-dihydrobenzimidazo[1,2-C]quininazolin-6-one carboxylic acid, its esters and method of synthesis thereof
GB0600764D0 (en) * 2006-01-13 2006-02-22 Crysoptix Ltd Organic compound, optical crystal film and method of production thereof
US8207185B2 (en) 2006-10-12 2012-06-26 Duke University CaMKKβ as a target for treating obesity
JP5464395B2 (ja) 2008-02-01 2014-04-09 大陽日酸株式会社 重水素化された芳香環又は複素環を有する化合物の製造方法
WO2009154754A2 (en) 2008-06-17 2009-12-23 Concert Pharmaceuticals, Inc. Synthesis of deuterated morpholine derivatives
WO2010033511A1 (en) 2008-09-16 2010-03-25 Concert Pharmaceuticals, Inc. Deuterated 2-amino-3-hydroxypropanoic acid derivatives
WO2012024255A2 (en) 2010-08-16 2012-02-23 Duke University Camkk-beta as a target for treating cancer
WO2012064618A1 (en) * 2010-11-09 2012-05-18 Crysoptix Kk Negative dispersion retardation plate and achromatic circular polarizer
CN103702961A (zh) 2011-05-23 2014-04-02 赛诺菲 含有n-烷基的氘代化合物的制备方法
CN104684555A (zh) 2012-09-18 2015-06-03 奥斯拜客斯制药有限公司 囊泡单胺转运体2的氘化苯并喹啉抑制剂的制剂药代动力学
EP2935251A1 (en) 2012-12-20 2015-10-28 Concert Pharmaceuticals Inc. Deuterated alk inhibitors
AU2014250762A1 (en) 2013-04-12 2015-10-29 Achillion Pharmaceuticals, Inc. Highly active nucleoside derivative for the treatment of HCV
RU2675270C2 (ru) 2013-10-17 2018-12-18 Вертекс Фармасьютикалз Инкорпорейтед Сокристаллы и содержащие их фармацевтические композиции
AU2019326448A1 (en) 2018-08-20 2021-03-11 Duke University Methods and compositions for drugs to treat ophthalmic diseases

Also Published As

Publication number Publication date
WO2020041344A4 (en) 2020-03-26
WO2020041344A1 (en) 2020-02-27
KR20210049857A (ko) 2021-05-06
MX2021002028A (es) 2021-07-21
SG11202101522WA (en) 2021-03-30
CA3109809A1 (en) 2020-02-27
BR112021003189A2 (pt) 2021-05-11
EP3840745A1 (en) 2021-06-30
US12221447B2 (en) 2025-02-11
AU2019326448A1 (en) 2021-03-11
IL280952A (en) 2021-04-29
JP2021534202A (ja) 2021-12-09
EP3840745A4 (en) 2022-06-08
CN112654353A (zh) 2021-04-13
CO2021003607A2 (es) 2021-07-30
US20210198266A1 (en) 2021-07-01
US20250122209A1 (en) 2025-04-17

Similar Documents

Publication Publication Date Title
US20250122209A1 (en) Methods and compositions for drugs to treat ophthalmic diseases
EP2564853B1 (en) Compositions comprising corticosteroid prodrug such as dexamethasone palmitate for the treatment of eye disorders
US10596179B2 (en) 3-(4-((4-morpholinomethyl-benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus
JP6509307B2 (ja) α−２Ｂアドレナリン受容体作動薬を用いて制御性Ｔ細胞を活性化する方法
JP6893917B2 (ja) 神経変性疾患の処置
HUE028499T2 (en) Janus kinase inhibitors for the treatment of dry eye and other eye-related diseases
KR20110042054A (ko) 축성 근시의 예방 또는 치료제
KR20150139501A (ko) 안과용 제형
KR20120115344A (ko) 안압을 감소시키는 혼합물, 키트 및 방법
CN1703227A (zh) 治疗神经疾病的方法和组合物
WO2021066144A1 (ja) ヘテロシクリデンアセトアミド誘導体含有医薬
US10537563B2 (en) Methods for treating ocular disease using inhibitors of CSF-1R
JP2023506118A (ja) 皮膚エリテマトーデス及び扁平苔癬（ｌｐ）の治療のためのｊａｋ１阻害剤の使用
WO2024029597A1 (ja) ＩＦＮ－γへ選択的に結合するＤＮＡオリゴヌクレオチドを含有するドライアイ治療薬
US20250120956A1 (en) Azole Compounds for Enhancing Telomerase Reverse Transcriptase (TERT) Expression
Golmohammadi et al. A comprehensive review of the effects of tacrolimus (FK-506) on dry eye disease (DED): Focus on inflammation
JP2003104909A (ja) Ｐｉ３キナーゼ阻害作用を有する化合物を有効成分とする緑内障治療剤
HK1085125A (en) Methods and compositions for treatment of neurological disorder
WO1997005871A1 (en) Nitric oxide synthase (nos) inhibitors
HK1232801B (en) 3-(4-((4-(morpholinomethyl-benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus
HK1232801A1 (en) 3-(4-((4-(morpholinomethyl-benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus
JP2004083578A (ja) レボカバスチンとペミロラストの組み合わせからなる治療剤
JPH11511138A (ja) 酸化窒素シンターゼ（ｎｏｓ）阻害剤